Table 1.
Demographic and patient characteristics for short- and long-term survivors
| Characteristics | Survive ≤5 y (n = 1115) | Survive 8+ y (n = 260) | P a |
|---|---|---|---|
| Mean age (SE), y [No.] | 60.43 (0.33) [1003] | 58.01 (0.68) [244] | .001 |
| Race or ethnicity, No. (%) | |||
| American Indian | 4 (0.4) | 1 (0.4) | .07 |
| Asian | 58 (5.2) | 23 (8.8) | — |
| Black | 50 (4.5) | 8 (3.1) | — |
| White non-Hispanic | 949 (85.1) | 211 (81.2) | — |
| Hispanic | 37 (3.3) | 14 (5.4) | — |
| Unknown | 17 (1.5) | 3 (1.2) | — |
| Treatment, No. (%) | |||
| Chemotherapy | 387 (34.7) | 91 (35.0) | .18 |
| Chemotherapy + bevacizumab | 376 (33.7) | 74 (28.5) | — |
| Chemotherapy + bevacizumab + bevacizumab | 352 (31.6) | 95 (36.5) | — |
| Stage, No. (%) | |||
| III | 775 (69.5) | 213 (81.9) | <.001 |
| IV | 340 (30.5) | 47 (18.1) | — |
| Grade, No. (%) | |||
| 1 | 31 (3.1) | 17 (7.01) | .02 |
| 2 | 125 (12.5) | 30 (12.3) | — |
| 3 | 847 (84.4) | 197 (80.7) | — |
| Performance status, No. (%) | |||
| 0 | 477 (47.0) | 90 (54.2) | <.001 |
| 1 | 458 (45.2) | 69 (41.6) | — |
| 2 | 79 (7.8) | 7 (4.2) | — |
| Residual disease, No. (%) | |||
| ≤1 cm | 479 (43.0) | 144 (55.4) | <.001 |
| >1 cm | 636 (57.0) | 116 (44.6) | — |
| FACT-O-TOIb at baseline, mean (SE) [No.] | 66.26 (0.49) [968] | 68.89 (0.99) [238] | .02 |
| FACT-O-Physical Well-Beingb at baseline, mean (SE) [No.] | 19.83 (0.17) [967] | 21.04 (0.36) [238] | .002 |
| FACT-O-Functional Well-Beingb at baseline, mean (SE) [No.] | 14.30 (0.19) [968] | 14.94 (0.40) [238] | .15 |
| FACT-O-Additional Concernsb at baseline, mean (SE) [No.] | 32.15 (0.20) [968] | 32.93 (0.40) [238] | .08 |
| Abdominal Discomfortc at baseline, mean (SE) [No.] | 11.48 (0.12) [968] | 12.32 (0.24) [238] | .002 |
a
Differences for categorical variables are tested with a 2-sided Pearson χ2 test; difference in mean age is tested using a 2-sided t test.
b
Means for FACT-O-TOI and subdomains are adjusted for age, stage, grade, performance status, residual disease, and treatment. Higher scores reflect better quality of life. Differences are tested with a 2-sided F test.
c
Mean scores are adjusted for age, stage, grade, performance status, residual disease, and treatment. Higher scores reflect less abdominal discomfort. Differences are tested with a 2-sided F test.